This article is part of the supplement: 15th Paediatric Rheumatology European Society (PreS) Congress
Poster presentation
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
1 Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands
2 Leiden University Medical Centre, Leiden, Netherlands
3 AMC Emma Children's Hospital, Amsterdam, Netherlands
4 UMCG Beatrix Children's Hospital, Groningen, Netherlands
5 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
6 Academic Hospital Maastricht, Maastricht, Netherlands
7 Hagaziekenhuis Juliana Children's Hospital, Den Haag, Netherlands
8 Utrecht MC Wilhelmina Children's Hospital, Utrecht, Netherlands
Pediatric Rheumatology 2008, 6(Suppl 1):P40 doi:10.1186/1546-0096-6-S1-P40
Published: 15 September 2008First paragraph (this article has no abstract)
The aim of etanercept therapy in juvenile idiopathic arthritis (JIA) is to achieve disease remission. However, little is known about when or how to stop etanercept when this aim is reached. Our objective was to describe characteristics and disease course of JIA patients who discontinued etanercept because of a sustained good clinical response.